Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
New York multi-studio fitness membership for yoga, cycling, and spa across 30+ countries; Mindbody-acquired competing with Gympass/Wellhub for multi-venue fitness subscription and corporate wellness benefits.
ClassPass is a New York-based fitness and wellness membership platform providing access to thousands of gyms, yoga studios, pilates, cycling, strength training, spa, and beauty services through a single subscription — enabling members to sample multiple fitness and wellness experiences rather than committing to a single-location gym membership. Acquired by Mindbody (in turn backed by Vista Equity Partners) in 2021 for approximately $500-700 million, ClassPass serves millions of members across 30+ countries, generating estimated $400+ million in annual revenue and becoming the largest multi-venue fitness subscription platform globally.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.